Loading
Developed the MANAFEST assay to track the tumour-specific T cells that immunotherapy awakens.
Kellie N. Smith is Associate Professor of Oncology at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a T-cell immunologist known for developing the MANAFEST assay, which detects and tracks the mutation-associated neoantigen-specific T cells that immunotherapy awakens. Her selected paper describes MANAFEST as a functional assay for neoantigen-specific T cells. She now applies these assays to neoadjuvant immunotherapy trials, with relevance to checkpoint inhibitors and personalised neoantigen vaccines.
| Title | Journal | Year |
|---|---|---|
| MANAFEST: a functional assay to detect and track mutation-associated neoantigen-specific T cells | Cancer Immunology Research | 2018 |
Shares Cancer Immunology Research, Immune checkpoint inhibitors.
Shares Cancer Immunology Research, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Immune checkpoint inhibitors.
Shares Cancer Immunology Research, Immune checkpoint inhibitors.
Shares Neoantigen, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/